As part of Myeloma Patients Europe’s (MPE) ongoing work to ensure that the patient voice is fully represented, and to strengthen organizations’ and individuals’ ability to advocate effectively, in 2017 MPE created the Advocate Development Program (ADP). The ADP is a 12-month training programme designed to develop participants’ advocacy knowledge and skills to better serve patients locally, nationally, and across Europe. Through the course, participants improve their understanding of clinical research and development, mechanisms of accessing diagnostics and drugs, interaction with stakeholders including clinicians and industry, and the basics of evidence-based advocacy. Continue reading
Myeloma Patients Europe (MPE) has put together an advice sheet for our members and myeloma patients on coronavirus (Covid-19). This advice has been reviewed by our scientific advisors and will be continually updated to reflect the latest information.
Dr Faith Davies, NYU Langone Hospital, New York, USA, explains in this video the pre-clinical myeloma updates presented in the American Society of Hematology (ASH) Annual Meeting 2019 and why are those important to patients. Continue reading
ASH 2019, Orlando – A number of early-phase studies were presented yesterday during the 61st American Society of Hematology (ASH) Annual Meeting spotlight the rapid advances being made in cellular immunotherapy for blood cancers. Researchers will present the results of early-phase studies of emerging “second-generation” cellular immunotherapy products that strive to overcome the limitations of existing products. Continue reading
It is with great sadness that we share that our friend, colleague and Board member Lisa Kotschi passed away in the night of the 21st November 2019. Continue reading
Myeloma Patients Europe (MPE) recently held the first face-to-face meeting of the Advocate Development Programme (ADP) in Stockholm, Sweden during the European Haematology Association (EHA) Annual Congress 2018. Continue reading
MPE is inviting members to express their interest in participating in a small pilot on patient information for newly diagnosed myeloma patients.
As part of this pilot, MPE will be adapting and translating an Infopack for newly diagnosed patients (created by Myeloma UK) for use in small group of European countries. The Infopack provides information that patients may need to know following the diagnosis of myeloma and provides practical tips.
The European Commission has issued a legislative proposal to the European Council and European Parliament on further integration of health technology assessment (HTA) in the EU.
Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2017.
The talk will be given by Dr María Victoria Mateos, Associate Professor of Hematology and Consultant. Physician of the Haematology Department at the University Hospital of Salamanca, Spain. Continue reading
As part of the Advocate Development Programme (ADP), MPE is organising an online webinar about science in patient advocacy. Although the webinars held within the ADP are usually open only to our ADP trainees, on this occasion we would like to invite to the webinar all our members and patient advocates interested in science. The webinar “Science in patient advocacy” will be given by Bettina Ryll, chair of the ESMO Patient Advocates Working Group (PAWG) and founder of the Melanoma Patient Network Europe (MPNE).